Drug Type Small molecule drug |
Synonyms EBI 2554, SHR 2554, SHR2554 |
Target |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN), Special Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral T-Cell Lymphoma | Phase 3 | CN | 17 Jan 2024 | |
Follicular Lymphoma | Phase 2 | CN | 01 Apr 2024 | |
Refractory Classic Hodgkin Lymphoma | Phase 2 | CN | 14 Jun 2023 | |
Castration-Resistant Prostatic Cancer | Phase 2 | US | Treeline Biosciences, Inc.Startup | 12 Feb 2023 |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Sep 2020 | |
B-Cell Lymphoma | Phase 2 | CN | 01 Sep 2020 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 20 Nov 2018 | |
Classical Hodgkin's Lymphoma | Phase 1 | CN | 01 Jul 2022 | |
T-Cell Lymphoma | Phase 1 | CN | 01 Jul 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | US | 30 Jan 2022 |
Phase 2 | Sarcoma INI1 Loss | 9 | kawjpnmbwv(qnpbipbocy) = oqziuvrrxd oonliirusk (rwfvhddqug, 1.2-NA) View more | Positive | 23 Oct 2023 | ||
NCT04407741 (ASCO2023) Manual | Phase 1 | 32 | pjkimzkpep(bdejvknstt) = SHR2554 350mg bid plus SHR-1701 30mg/kg q3w hvfuzvsdez (wibmcbqpgv ) View more | Positive | 31 May 2023 | ||
NCT03603951 (Pubmed) Manual | Phase 1 | 113 | oytrmzmock(xjrspgztvn) = hyqmtlvkzw ggykomqbzb (xkspukipql ) View more | Positive | 01 Jul 2022 | ||
Phase 1 | 113 | qabalalogj(abbcsnbzoa) = etkrzhaduo ghhcgblbnq (ddotmxtksb, 42.1 - 73.7) View more | - | 02 Jun 2022 |